Rome Ther­a­peu­tics ad­vances dark genome drug af­ter com­plet­ing $72M Se­ries B ex­ten­sion backed by Big Phar­ma

Dark genome-fo­cused biotech Rome Ther­a­peu­tics has com­plet­ed an over­sub­scribed $72 mil­lion Se­ries B ex­ten­sion sup­port­ed by new Big Phar­ma back­ers, with an eye to ad­vanc­ing its lead an­ti-in­flam­ma­to­ry pro­gram in­to clin­i­cal tri­als.

The Boston-based com­pa­ny raised $77 mil­lion in its orig­i­nal Se­ries B round in Sep­tem­ber 2021 and has now com­plet­ed the ex­ten­sion phase sup­port­ed by in­vestors, in­clud­ing the ven­ture arms of Sanofi, Bris­tol My­ers Squibb and John­son & John­son, bring­ing the to­tal to $149 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER